Please login to the form below
Shining a light on the true cost of patient care
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore how the proposed national patient data sharing scheme would change the NHS
When
Sir John Bell recently published his recommendations for the Life Sciences
strand of the Government’s Industrial Strategy, he said that the NHS’s
structure gives it data sharing opportunities that cannot be realised in many
insurance-based healthcare systems.
His vision for a national patient data sharing scheme that
would give researchers, including private companies, faster access to
“de-identified” patient data from millions of records, would transform the
NHS’s silo-based system, exposing anomalies in patient care and revealing the
true cost of care.
While
industries ranging from retail to insurance have been successfully harnessing
big data for years to improve products and services, the NHS has struggled to
capitalise on complex data. This is partly because primary and secondary care
datasets have not been linked, and patient data from social care, charities and
other related fields are also stored in silos.
In recent years, there has been a clear move towards
gathering data within the NHS for benchmarking purposes. Unfortunately, however, trusts
do not have access to Hospital Episodes Statistics (HES) data to benchmark
themselves against each other. Furthermore,
they do not have the capacity to drill down into the data that is currently
available to them to gain deeper insights into how all services are currently performing,
and where problems and inefficiencies exist.
As the NHS struggles to afford to capture,
procure and analyse its own data, there is a huge opportunity for pharma to
help shape the way that NHS services are delivered by gathering this data
themselves, analysing it and sharing the findings with CCGs, NHS trusts and new
emerging organisations.
Indeed,
if it could be proved that changes could improve patient care and drive down
costs, pharma may be able to present an initial ‘case for change’ for a particular patient pathway, which could
then lead to a detailed business case being developed by a multi-disciplinary
group. This can help pharma build relationships with the NHS in
an increasingly tough economic environment.
How would a national patient data sharing
system change the NHS?
Sir John’s proposals would involve a major escalation of
the data collection and integration schemes that are currently underway in some
parts of the country, so that proposed regional data hubs could ultimately feed
into a national data lake.
If regional data hubs and a national data lake were
created across the UK, then anomalies in patient care and outcomes, and their
financial impact, would become increasingly apparent. This would lead to a
greater focus on delivering optimal patient journeys – like those already
defined by NHS Rightcare for various conditions.
To
manage these kinds of costs, Sustainability and Transformation Partnerships
(STPs) are likely to integrate their budgets
into an Accountable Care System (ACS).
The ACS model involves a group of providers being responsible for all
the healthcare needs of a defined population in order to improve outcomes and
reduce costs across a defined area. Joined up data systems measure the inputs and
outcomes necessary to implement new outcomes based capitated fee contracts -
the fundamental building blocks of accountable care. They mean that costs that
were once hidden away among a variety of different providers will be very
visible within regional population datasets.
The UK’s potential to become a major data centre
The advantages of gathering and
integrating data from multiple touchpoints across the UK are immense and they
could eventually see the NHS used as a laboratory for international
organisations to test theories and measure costs across a wide variety of care
settings to
support the introduction of new, innovative technologies and treatments.
They could also allow accelerated
access products, such as cancer immunotherapy drugs, to generate real world
data quickly to support clinical trial findings. This could give costly, but
highly effective drugs a competitive advantage, if it could be proven, through
real world data, that they will save money in the longer term.
However, before this can happen, the
Government has a huge reputational hurdle to overcome, following the care.data
debacle. It must earn patients’ trust about the use of confidential medical
data and reassure them that third parties can be trusted to use data
responsibly.
Conclusion
The NHS is one of the few health systems in the world
that is truly national. If it could amass and share patient data from a full
range of care providers in different settings, it would indeed have the potential
to become a global health information leader.
There is, of course, a clear gap between where the NHS is
now in its data gathering and interpretation capacity and where it wants to be.
To bridge this gap, there is a valuable role for pharma to play in supporting
local trusts and CCGs to analyse and interpret the data that they currently
hold, and in publicising its success in harnessing patient data to improve care.
Pharma
also needs to be thinking ahead about how its products and services can improve
outcomes and reduce costs, as the NHS moves towards a system where it may soon
be able to evaluate the industry’s worth more accurately through the power of
patient data.
Ends
Paul
Midgley is Director of NHS insight and Sue Thomas is CEO of the Commissioning
Excellence Directorate, both at Wilmington Healthcare. For information on
Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
Contact
Website
Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom
- UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
- Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this latest quick-read briefing, Oli Hudson, Content Director at Wilmington Healthcare, lifts the veil on what place is, how it works and why it matters.
Wilmington Healthcare
- MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
- With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is it responding to this challenge, and what can industry do to support it? Oli Hudson, Content Director at Wilmington Healthcare, explains what’s changing and how industry should respond.
Wilmington Healthcare
- ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
- With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes and why they matter for pharma and med-tech companies.
Wilmington Healthcare
- HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
- Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to the NHS and its prescribing behaviours during the peak of the pandemic. Oli Hudson summarises five of the key findings:
Wilmington Healthcare
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Wilmington Healthcare
- Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare